The impact of regular bisoprolol on the response to salbutamol in asthma: A double‐blind randomized placebo‐controlled crossover trial

Miriam Bennett, Catherina L. Chang, Chris Tuffery, Sandra Hopping, Robert J. Hancox

Respirology · 2020 · 11 citations · 31 references

Concepts

Abstract

ABSTRACT Background and objective Non‐selective beta‐blockers impair the bronchodilator response to beta 2 ‐agonists. Cardio‐selective beta 1 ‐blockers are less likely to cause this effect, yet they remain relatively contraindicated in asthma. We investigated whether the response to salbutamol is impaired during cardio‐selective beta 1 ‐blocker treatment in people with asthma. Methods A random‐order, double‐blind, placebo‐controlled, non‐inferiority, crossover study was conducted comparing up to 5 mg bisoprolol daily for 2 weeks with matching placebo, with an open‐label extension of up to 10 mg bisoprolol daily. After each treatment period, mannitol was inhaled to induce bronchoconstriction with a 15% fall in forced expiratory volume in 1 s (FEV 1 ). Immediately after mannitol challenge, salbutamol (100, 100 and 200 μg) was administered via spacer at 5‐min intervals with repeated FEV 1 measures. The FEV 1 recovery with salbutamol was measured as an area under recovery curve (AUC). Based on earlier research, a clinically relevant non‐inferiority limit of a 30% reduction in the AUC was set. Results A total of 19 adults with mild asthma and positive inhaled mannitol challenge completed the study. Adjusting for the FEV 1 fall induced by mannitol and treatment sequence, the mean AUC response to salbutamol after bisoprolol was 5% lower than after placebo, with a one‐sided 95% confidence interval (CI) of 26% lower. Thirteen participants completed the open‐label extension up to 10 mg bisoprolol daily with mean AUC 11% higher after bisoprolol with a 95% CI of 5% lower. Conclusion The bronchodilator response to rescue salbutamol after mannitol‐induced bronchoconstriction is non‐inferior during regular treatment with the cardio‐selective beta 1 ‐blocker, bisoprolol, compared to placebo. Clinical Trial Registration: ACTRN12618000306213 at https://www.anzctr.org.au

References

31